BRAF targets in melanoma. Biological mechanisms, resistance, and drug discovery. Cancer drug discovery and development. Volume 82. Ed. Ryan J. Sullivan. Springer (2015)
In conclusion, targeted therapy with BRAF and MEK inhibitors as monotherapy or in combination represents a major step forward in the management of patients with BRAF mutant melanoma. Although dramatic and rapid responses occur in the majority of patients, acquired resistance limits the duration of benefit for these patients. Improved combinations of targeted therapies to forestall acquired resistance are urgently needed. Currently, ongoing clinical trials are evaluating BRAF inhibitors in conjunction with MEK inhibitors as well as a large variety of other targeted agents. Agents targeting ERK, the final common signaling partner in the MAPK pathway are also ongoing. Additionally, the combination of immune therapies with these agents is an intriguing avenue to pursue (see Chap. 9).
[contact-form-7 id=»5168″ title=»Контактная форма 1″]